Company ProfilePremium

Terragen Holdings Limited

Company Profile Analysis

Ticker: TGH.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Terragen Holdings Limited - Company showcase

Year Founded & Workforce

1996

Terragen Holdings Limited logo

Terragen Holdings Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Terragen Holdings Limited Overview

Terragen Holdings is a Queensland-based agricultural biotechnology company. It develops, manufactures and sells live-microbe ("probiotic") products for livestock and crops. Its commercial portfolio has four lines:

  • Mylo®, a liquid ruminant feed supplement

Terragen Probiotic for Ruminants™ (TPR): and TPR Ultra, a dry-format probiotic aimed at beef and lamb feedlots

  • Great Land Plus® (GLP), a liquid plant biostimulant and soil conditioner

  • Naturalift®, a consumer home-garden probiotic launched in November 2025

The company sits at the very early, sub-scale end of the global agricultural biologicals industry. FY2026 revenue was A$1.43 million against a net loss of A$3.75 million, and the business is funded by periodic equity raisings and R&D tax refunds. Its investment case rests on converting large independent trials into recurring feedlot volume and North American market access:

  • A 10,600-head Mort & Co / MLA trial, externally funded up to A$2.8 million

  • A first commercial feedlot contract (Ravensworth)

  • A Canadian government feedlot study

  • A US regulatory filing that the company expects to be approved in December 2026


Company's own description (paraphrased from the FY2026 Annual Report)

The company describes itself as an Australian agricultural biotechnology business. It applies proprietary microbial technology to improve animal health and productivity, crop performance and soil health.

Its stated principal activities are research, development and commercialisation of biological products that enhance animal and plant health for use in agriculture. Management said FY2026 marked a shift in focus from product development and launch towards commercial validation and broader market adoption.

The Annual Report positions:

  • the animal probiotics (Mylo® and TPR) as feed supplements that lift average daily weight gain and reduce methane production, and

  • Great Land Plus® as a biostimulant that reduces reliance on chemical fertilisers while increasing yields and soil organic carbon.

Independent characterisation

Terragen is best understood as a single-technology-platform, pre-scale biologicals developer with a thin commercial revenue base. Its core competence is selecting, fermenting and formulating naturally occurring bacterial consortia. Lactobacillus and Acetobacter genera are cited in IPO-era descriptions of Great Land. It then validates them through field trials.

Commercially, the company behaves like a branded input supplier selling through Australian agri-retail channels. These include Nutrien Ag Solutions, whose national supply agreement was extended in the June 2026 quarter to cover TPR as well as GLP, plus a network of retail agency partners and online sales. It also sells directly to large feedlots.

Four features stand out:

  1. Concentration. Two unnamed customers each contributed more than 10% of FY2026 revenue: Customer A with A$200,533 and Customer B with A$158,036. Together they account for about 25% of sales (FY2026 Annual Report Note 5).

  2. Animal-led mix. Animal probiotics were 78.4% of FY2026 sales and plant biostimulants 21.6% (Note 3).

  3. Australian dependence. Australia contributed 98.1% of FY2026 revenue (Note 5).

  4. Subsidy-assisted economics. The R&D tax incentive (A$642,691 in FY2026) was equivalent to 45% of revenue and is now presented within "other income".

Revenue model

Revenue typePresenceComment (source: FY2026 Annual Report, Note 3 and accounting policy)
Product sales100% of revenueRecognised at a point in time on delivery. Sales are made directly to customers and through agri-retail.
ServicesNone disclosedTrial programmes are funded by partners (e.g., the MLA Donor Company) but are not booked as service revenue.
Subscription—Not applicable
Licensing / royaltiesNone to dateThe company states its long-term viability depends partly on entering licensing or distribution arrangements. A North American distribution agreement is targeted (expected January 2027 per the Q4 FY2026 report).
Other income (non-revenue)MaterialR&D tax incentive A$642,691, interest A$153,499 and freight recovery A$3,069 in FY2026

Value-chain position

Terragen operates across these stages:

Upstream: proprietary strain library and IP (patents across Australia, New Zealand, the US and Europe, per the FY2026 risk table)

Midstream: manufacturing at its Coolum facility under GMP standards prescribed by the APVMA. Liquid Mylo and GLP, and dry TPR, are made at commercial scale. US manufacturing partners are scaling up TPR strain production (Q4 FY2026 report).

Downstream: branding, veterinary and product-manager sales support, retailer distribution, and installation of automated microbial dispensers at feedlots (Grassdale in May 2026; Ravensworth is a condition precedent)

Customer types and end-markets

End-marketProductsCustomer type
Dairy (calves and cows)Mylo® Calves / Mylo® CowsDairy farmers in Australia and New Zealand; NZ via distributor Nutritech International (appointed 2023)
Beef feedlots and grass-fed beefTPR, TPR Ultra, Mylo® BeefFeedlot operators (Ravensworth, Mort & Co Grassdale)
Lamb / sheepDry Mylo / TPR, Mylo® LambLamb feedlots and producers
Broadacre and horticulture croppingGreat Land Plus® (including a pasture variant)Growers of maize, canola, winter cereals and horticulture (e.g., avocado trials)
Consumer home gardenNaturalift®Australian households, via online channels
Companion animals (pipeline)Canine probioticPet owners and veterinary channel (not yet commercial)

Strategy

Stated strategy (themes paraphrased from the FY2026 Chair and MD report)

The company's FY2027 framing is to turn scientific validation and commercial trials into sustainable revenue growth. It does this by proving performance at commercial scale and building the partnerships and distribution channels needed to reach larger markets.

Its three stated FY2027 priorities:

  1. Feedlot adoption of TPR, through the Ravensworth supply agreement, the Mort & Co Grassdale trial and broader feedlot engagement.

  2. International expansion, through the Canadian trials, regulatory approvals and North American commercial partnerships.

  3. Revenue diversification, by growing GLP, Naturalift and companion-animal opportunities while advancing next-generation microbial technology.

The Board describes its approach as disciplined investment, commercial execution and partnership-led adoption.

Initiatives announced in the last 24 months

InitiativeDateDetailStatus
TPR / TPR Ultra dry-format launch25 Mar 2025Opens beef and lamb feedlot segmentsCommercial; transition from Mylo is slower than planned
Naturalift® consumer launchNov 2025First consumer-channel productCommercial (online)
A$7.0M placementFeb–Mar 2026318.2M shares at A$0.022; Ward entities subscribe A$2.25MCompleted
GLP maize silage validation3 Mar 2026Laconik independent assessment: +12% yieldCompleted
Ravensworth Feedlot supply agreement28 May 2026Minimum 360,000 TPR doses plus GLP. Conditions: a Terragen-funded dispenser and Ravensworth's feedlot expansion. Order due by the later of 1 Dec 2026 or 90 days after conditions are met. 12-month term from first delivery (late CY2026).Conditional
Mort & Co / MLA Donor Company trialMay 2026 – Dec 2026Up to 10,600 head, 20 replicated data sets, Charles Sturt University protocols, carcass evaluation at Kilcoy; externally funded up to A$2.8M. A supply agreement with Mort & Co is executed but conditional on trial success.In progress; data expected Jan 2027
Nutrien national supply agreement extensionJun quarter 2026Extends to TPR alongside GLP; more than 700 locationsExecuted
North American market accessOngoingKnoell as regulatory consultant; US approval expected Dec 2026; AAFC feedlot study; US manufacturing scale-up; distribution agreement targeted Jan 2027In progress
QUT / Food Agility nitrogen-efficiency microbesOngoingThree formulations in greenhouse trialsR&D
FAR Australia / COGGO winter crop trials2026 seasonIndependent benchmarkingIn progress
Canine probioticOngoingSafety, palatability and SCFA work done; microbiome data due Nov 2026Pre-commercial

Medium-term targets and guidance

The company gives no formal revenue or earnings guidance. Its only quantified forward statement, from the Q4 FY2026 report, says the two supply agreements plus current sales could lift TPR use to 160,000 head of beef cattle in CY2027. That outcome assumes:

  • a successful Mort & Co trial and subsequent orders;

  • Ravensworth using TPR across operations of up to 40,000 head per day, then extending it across the whole feedlot; and

  • stable existing TPR sales.

The 28 May 2026 announcement also referenced a potential 25–50% sales increase in early 2027 contingent on KPIs (as summarised by InvestSMART).

ESG and cost targets: no formal emissions or cost-reduction targets have been disclosed.

Products & Services

Animal Probiotics

1. Mylo® (liquid) — Mylo® Calves, Mylo® Cows, Mylo® Beef, Mylo® Lamb

Description: a liquid microbial feed supplement containing a selected blend of live, naturally occurring microbes. It is described as antibiotic- and hormone-free and certified organic (Nov 2025 investor deck). IPO-era descriptions credit the company's "AmpliBoost" technology.

Claimed benefits: - Higher average daily weight gain and reduced methane production (FY2026 Annual Report)

  • Calf growth and health

  • Cow productivity: the Harrisville, QLD longitudinal dairy study was released in FY2023

Target customers: dairy farmers in Australia and New Zealand, plus some beef and lamb producers

Launch: on market by 2018

Pricing: not publicly disclosed

Status: customers are being transitioned to dry-format TPR. Management says this transition is taking longer than expected as customers work through existing Mylo inventory (FY2026 Annual Report).

2. Terragen Probiotic for Ruminants™ (TPR) — dry format

Description: a dry-format version of the Mylo microbial technology ("Dry Mylo") developed for feedlots. Development took more than 18 months and covered prototyping, dose-rate optimisation, formulation, stability and compatibility testing, and field trials.

Launch: 25 March 2025 (FY2026 Annual Report). The 1H FY2026 report says late April 2025.

Channels: online, leading Australian agri-retailers, and Nutrien Ag Solutions (added June quarter 2026). Feedlots are supplied direct through automated dispensers.

Evidence base: - A Charles Sturt University controlled feeding trial: about A$57 more value per carcass and up to 4.7% heavier live weight after a 100-day programme. Terragen cites an ROI of about 9x at NFAS pricing (Q4 FY2026 report).

  • An earlier dry Mylo lamb weight-gain study

Commercial traction: an 87% quarter-on-quarter uplift in TPR sales was reported in a late-2025 quarterly (as cited by TradingView). The Ravensworth contract has a minimum of 360,000 doses.

3. Terragen Probiotic Ultra for Ruminants™ (TPR Ultra)

Description: a premium or higher-specification variant launched alongside TPR in March 2025, targeted at feedlots

Current use: the formulation in the 10,600-head Mort & Co / MLA trial

Pricing: not publicly disclosed

Plant Bio-stimulants

4. Great Land Plus® (GLP)

Description: a patented liquid biological soil conditioner and plant biostimulant. IPO-era descriptions cite live Lactobacillus and Acetobacter species. Claimed benefits include greater nutrient availability, root development, stress tolerance, soil organic carbon and reduced chemical fertiliser use.

Variant: a Great Land Plus Pasture® variant appears in the Nov 2025 deck

Evidence base: - Independent Laconik assessment (announced 3 March 2026): a 12% maize silage yield uplift at 4 L/ha across 13 replicated data sets, worth about A$1,100/ha extra gross revenue and an estimated ROI of up to 20x

  • Bundaberg avocado trial (pre-IPO): a 10% yield benefit

  • Applied research on maize and canola (capitalised development costs, FY2026 Note 11)

Customers: broadacre and horticultural growers, Ravensworth (bundled with TPR), and Mort & Co Fertilisers (purchase order 4 February 2026)

FY2026 revenue (category): A$308,876, up 16.2%

5. Naturalift® (consumer garden probiotic)

Launch: November 2025, through dedicated online channels with nationwide distribution

Description: an organic plant probiotic range for lawns, gardens, indoor plants and home horticulture, using the GLP microbial technology

Revenue contribution: not separately disclosed (included within plant bio-stimulants)

Pipeline (not yet commercial)

ProgrammeDescriptionStatus (latest source)
Canine probiotic (Terragen Probiotic® Companion Animal)First companion-animal productInvetus safety and palatability trial completed. Faecal short-chain fatty acid analysis showed positive shifts. Microbiome sequencing results were due in November 2026. Manufacturing and distribution partner discussions are ongoing. (Q4 FY2026 report)
Nitrogen-use-efficiency microbes ("Microbial Solutions for Agricultural Emissions")Strains that improve nitrogen use efficiency and promote plant growth; collaboration with QUT and Food Agility CRCThree formulations selected for greenhouse trials, with small-scale field work to follow (Q4 FY2026 report)
Winter-crop biologicalsBenchmarking GLP and new biologicals in cereals and canolaFAR Australia Biological Benchmarking Program and COGGO (WA) showcase trials under way (Q4 FY2026 report)
North American TPRUS and Canadian market access; US contract manufacturingKnoell expects US approval in December 2026. The AAFC feedlot study concludes in December 2026, with data expected in January 2027. (Q4 FY2026 report)
Brazil TPRRegulatory market accessEngagement in progress (FY2026 Annual Report)
Lactolin, HaloLegacy IPO-era products intended for the US and EuropeNo recent disclosure; current status not publicly disclosed

Financial Narrative

Income statement

Notes on the income statement:

  • FY2022–FY2024 EBIT and pre-tax figures are from the FY2023 release and the StockAnalysis/Kalkine aggregator.

  • Before FY2026, pre-tax losses exceeded net losses because the R&D incentive was booked as a tax benefit.

  • FY2025 and FY2026 EBIT is derived: pre-tax loss plus finance costs.

  • FY2025 and FY2026 EBITDA is derived: EBIT plus depreciation and amortisation (A$0.253M and A$0.428M).

Margins and growth

Revenue CAGR, FY2022–FY2026 (four years):

  • Statutory basis (A$2.89M to A$1.43M): −16.1% per year

  • Net-sales basis for FY2022 (A$2.20M): −10.2% per year

Balance sheet

Notes on the balance sheet:

Debt composition: FY2026 debt is chattel mortgages of A$0.251M plus lease liabilities of A$0.024M. FY2025 debt is insurance premium funding of A$0.176M, chattel mortgages of A$0.394M and leases of A$0.166M.

Net cash cross-check: Aggregator net cash for FY2022 to FY2024 is A$6.47M, A$4.07M and A$4.12M, using StockAnalysis definitions.

Going concern: The going-concern note relies on cash-flow forecasts showing sufficient cash through 31 March 2028.

Cash flow

FY2022–FY2024 free cash flow is from StockAnalysis (aggregator). FY2025 capex includes A$0.605M of capitalised TPR and GLP development costs.

FY2026 operating cash detail (Appendix 4C YTD, A$'000):

  • Receipts from customers: 1,394

  • R&D payments: (667)

  • Manufacturing and operating costs: (1,261)

  • Advertising and marketing: (253)

  • Staff: (2,648)

  • Administration and corporate: (1,024)

  • R&D tax incentive received: 989

  • Net operating cash flow: (3,378)

Liquidity:

  • Q4 FY2026 operating burn was A$0.984M, which the company equates to about 7 quarters of funding.

  • The Q1 FY2027 Appendix 4C (September 2026 quarter) is due by 31 October 2026 and had not been released at the research date.

Commentary: trends, inflections and drivers

Revenue. Revenue has fallen for three consecutive years, from A$3.28M statutory in FY2023 to A$1.43M in FY2026, roughly a 56% decline. Management attributes the FY2026 decline (FY2026 Annual Report) to:

  • drought across key target markets;

  • slower-than-expected adoption;

  • a protracted channel transition from liquid Mylo to dry TPR, as customers ran down existing inventory; and

  • long evaluation cycles at large feedlots.

The FY2024 decline of 35% is consistent with a downturn in dairy-calf Mylo demand and channel destocking.

Two positive inflections stand out:

  1. Plant biostimulant sales rose 16% in FY2026.

  2. Gross margin recovered from 49.0% to 59.3%. Cost of sales fell 29%, partly because FY2025 carried TPR launch production costs; employee costs within cost of sales fell from A$0.49M to A$0.12M.

Cost base. Operating expenses fell 6.9% to A$5.98M. Sales and marketing fell A$0.41M after the launch year. R&D rose 11.5% to A$1.22M, driven by the canine programme. Administration was flat at A$2.82M; it remains roughly twice revenue and is the main structural problem in the P&L. Employee benefits fell 10.9%, and termination benefits dropped from A$184k to A$41k.

Losses. Net loss has been stuck at A$3.0–3.75M for four years. Gross profit is too small to absorb a fixed cost base of about A$5.5–6.0M. Other income (mostly the R&D incentive) covers roughly 13–18% of costs. Per-share losses have fallen faster than absolute losses because the share count has more than doubled: weighted shares rose from 438.4M in FY2025 to 600.1M in FY2026, and shares on issue rose from 369.1M at 30 June 2024 to 823.2M at 30 June 2026.

Balance sheet. The balance sheet is clean: no bank debt, no goodwill, and A$7.25M of cash against A$1.09M of total liabilities. The equity line has grown only through raisings. Issued capital is A$57.9M against accumulated losses of A$49.0M, so about 85% of all capital ever contributed has been consumed by losses.

Cash flow. Free cash burn has averaged about A$3.5M per year over FY2022–FY2026. FY2026 burn was inflated by an inventory build of about A$0.48M (raw materials up from A$0.37M to A$0.74M) ahead of expected Ravensworth and Mort & Co volumes.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment (AUD)

SegmentFY2025FY2026

Australia revenue (AUD)

1,598,6171,404,261

New Zealand revenue (AUD)

16,63627,821

Total revenue (AUD)

1,615,2531,432,082

Revenue by Segment (AUD) — Australia segment result

SegmentFY2025FY2026

Australia segment result (AUD)

-3,745,941-3,774,583

New Zealand segment result (AUD)

22,11123,216

Group result (AUD)

-3,723,830-3,751,367

Segment Revenue

MetricAustraliaNew Zealand

Revenue YoY growth

−12.2%+67.2%

% of group revenue

98.1%1.9%

Segment result margin

−268.8%+83.4%

Segment assets (AUD)

10,527,45064,968

Additions to non-current assets (AUD)

153,2280

Revenue by Segment (AUD) by Product Category

Product categoryFY2025FY2026

Animal probiotics revenue (AUD)

1,349,3711,123,206

Plant bio-stimulants revenue (AUD)

265,882308,876

Revenue by Segment (%)

Product category (%)FY2026 YoYFY2026 share

Animal probiotics

−16.8%78.4%

Plant bio-stimulants

+16.2%21.6%

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue, statutory (AUD Mn)

2.893.282.141.621.43

Net sales net of commissions, company-reported (AUD Mn)

2.202.47———

Cost of sales (AUD Mn)

——0.770.820.58

Gross profit (AUD Mn)

——1.370.790.85

Other income incl. R&D incentive (AUD Mn)

———1.090.80

Sales and marketing expense (AUD Mn)

———1.731.31

R&D expense (AUD Mn)

———1.101.22

Admin and other expense (AUD Mn)

———2.752.82

Operating income excl. other income (AUD Mn)

———-4.78-4.51

EBIT (AUD Mn)

-6.29-3.97-3.85-3.69-3.71

EBITDA (AUD Mn)

———-3.44-3.29

Pre-tax income (AUD Mn)

-6.30-3.98-3.88-3.72-3.75

Net income (AUD Mn)

-5.41-3.23-3.01-3.72-3.75

EPS basic and diluted (A$ cents)

-2.80-1.57-0.87-0.85-0.63

Dividends per share (A$ cents)

00000

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue growth (%)

-19.713.2-35.9-24.4-11.3

Gross margin (%)

——64.049.059.3

Operating margin excl. other income (%)

———-296.0-315.2

EBITDA margin (%)

———-212.9-229.5

Net margin (%)

-187.2-98.5-140.7-230.5-262.0

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (AUD Mn)

———8.1210.59

Cash and equivalents (AUD Mn)

6.674.174.544.707.25

Trade and other receivables (AUD Mn)

———0.950.68

Inventories (AUD Mn)

———0.500.97

Intangible assets incl. patents and capitalised development (AUD Mn)

———0.890.76

Goodwill (AUD Mn)

00000

Short-term debt incl. leases (AUD Mn)

———0.420.11

Long-term debt incl. leases (AUD Mn)

———0.320.16

Total debt (AUD Mn)

———0.740.28

Net debt, negative = net cash (AUD Mn)

———-3.97-6.98

Total equity (AUD Mn)

——5.326.579.50

Working capital (AUD Mn)

———5.228.30

Issued capital (AUD Mn)

——46.9051.3057.88

Accumulated losses (AUD Mn)

——-43.27-46.99-48.99

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (AUD Mn)

———-3.03-3.38

Capex incl. intangibles (AUD Mn)

———0.680.18

Free cash flow (AUD Mn)

-4.95-2.86-2.35-3.71-3.55

Equity raised, gross (AUD Mn)

———4.767.00

Capital raising costs (AUD Mn)

———0.360.42

Dividends paid (AUD Mn)

00000

Buybacks (AUD Mn)

00000

R&D tax incentive cash received (AUD Mn)

———0.970.99

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2025FY2026Comment

ROE (%)

-62.7-46.7

Net loss divided by average equity

ROA (%)

not computed

-40.1—

Current ratio (x)

5.3410.34

Boosted by the A$7M placement

Debt / equity (x)

0.110.03

Hire purchase and leases only

Asset turnover (x)

not computed

0.15

Revenue divided by average total assets

DSO (days)

4241

Company-stated average credit period

DPO (days)

3231

Company-stated

DIO (days, year-end inventory / COGS)

220609

Inflated by bulk microbial strain purchases ahead of the TPR ramp

Cash conversion cycle (days)

about 230

about 619

Derived; distorted by the inventory build

NTA per share (A$ cents)

1.131.06

FY2026 Appendix 4E

Revenue by Region (AUD)

RegionFY2024FY2025FY2026

Australia revenue (AUD)

—1,598,6171,404,261

New Zealand revenue (AUD)

—16,63627,821

Rest of world revenue (AUD)

000

Total revenue (AUD)

2,137,0881,615,2531,432,082

Per-Share Data and Share Count (millions)

MetricFY2021FY2022FY2023FY2024FY2025FY2026

Share price at 30 June (A$ cents)

28.015.52.41.31.91.6

Shares on issue at 30 June (millions)

———369.1505.0823.2

Market capitalisation at 30 June (AUD Mn)

———4.89.613.2

Share Price & Returns

PeriodReturnBasis

1 year (Oct 2025 – Oct 2026)

Not precisely verified; price range A$0.014–0.030

Yahoo Finance 52-week range; last A$0.022 (2 Oct 2026)

3 years (from 30 Jun 2023 close of 2.4c)

About −8%

Derived, to A$0.022

5 years (from 30 Jun 2021 close of 28.0c)

About −92%

Derived

Since IPO (A$0.25 prospectus price)

About −91%

Derived; Stoxray shows −90.8% since IPO

Valuation Multiples

MultipleTerragenPeers

P/E

Not meaningful (loss)

—

EV / Sales

About 7.8x (EV of about A$11.1M = market cap A$18.1M − net cash A$7.0M; divided by revenue of A$1.43M)

MarketScreener shows EV/Sales of 2.92x for 2026 on an earlier, lower price and different EV basis.

EV / EBITDA

Not meaningful (negative EBITDA)

—

P/B

About 1.9x (A$18.1M / A$9.5M equity)

—

P/NTA

About 2.1x (A$0.022 / 1.06c)

—

Capital Markets

ItemStatus

Analyst consensus

None. No sell-side coverage identified.

Dividend history and policy

Never paid a dividend; no dividend reinvestment plan; franking 0%

Buybacks

None authorised or executed

Credit ratings (Moody's / S&P / Fitch)

Not rated

Debt maturity profile

Chattel mortgages A$0.251M (A$0.090M current, A$0.161M non-current) and leases A$0.024M (due within 1 year). All facilities mature within 4 years and are secured against assets with a written-down value of A$0.602M (Q4 FY2026 4C).

Liquidity of the stock

Average daily volume of about 81k shares (Yahoo), roughly A$1.8k per day, which is very illiquid

Index membership

None; not held by ETFs

Equity raising history (recent)

A$7.0M at A$0.022 (FY2026); A$4.76M at about A$0.035 (FY2025); about A$4.0M in 2023

Analyst Conclusions

Management guidance

No numerical revenue or earnings guidance has been given. Qualitative priorities are TPR feedlot adoption, North American access and diversification. The single quantified aspiration is TPR use of up to 160,000 head in CY2027, subject to trial success and customer scale-up. The going-concern forecast shows sufficient cash through 31 March 2028.

Consensus: none.

Bull case

  1. The trial converts into the first meaningful recurring revenue. Suppose the 10,600-head Mort & Co / MLA trial (data January 2027) replicates the Charles Sturt University result of about A$57 per carcass. Then Mort & Co orders begin under an already-executed supply agreement, and Ravensworth's minimum of 360,000 doses adds a floor. Even a fraction of the 160,000-head CY2027 scenario would represent a step-change from FY2026 animal-probiotic revenue of A$1.12M.

  2. North America re-rates the addressable market. US approval (expected December 2026), AAFC feedlot data and a North American distributor (targeted January 2027) could open royalty or distribution economics without Terragen building a sales force. That would be a potential licensing inflection against a roughly A$11M enterprise value.

  3. Scalable gross margin and a funded runway. Gross margin is already around 59%. The FY2026 raise funds operations to March 2028, so revenue growth could narrow losses without proportionate cost growth, because fixed administration of about A$2.8M does not scale with volume.

Bear case

  1. The commercial record is deteriorating, not improving. Revenue has fallen for three straight years to A$1.43M, and 1H FY2026 sales fell 26%. Each new product (TPR, Naturalift) has so far failed to offset decline elsewhere. The 160,000-head scenario rests on multiple conditions outside Terragen's control.

  2. Dilution remains the business model. Accumulated losses are A$49M against A$57.9M of capital raised. The share count rose 123% in two years. Burn of about A$3.4–3.6M per year means another raise is likely before FY2028, probably at a low price given illiquidity and the 33.7% blockholder.

  3. Execution and governance fragility. There have been five CFO arrangements in about 27 months, ending with a fractional outsourced CFO. The company has a single manufacturing site, roughly 25% customer concentration, and a distributor (Nutrien) building competing biologicals. Global majors with vastly greater R&D and distribution budgets compete in both of its product categories.

Key catalysts and monitorables (next 12 months)

Expected timingCatalyst / monitorable
By 31 Oct 2026Q1 FY2027 Appendix 4C: receipts trend, inventory drawdown, cash burn
Nov 2026Canine probiotic microbiome sequencing results; any partner agreement
27 Nov 20262026 AGM: director elections, remuneration report vote, any option or placement-capacity resolutions
By 1 Dec 2026 (or 90 days after conditions met)Ravensworth minimum order placement; dispenser installation and feedlot expansion
Dec 2026US market-access approval for TPR (Knoell estimate); AAFC study concludes; Mort & Co trial ends
Jan 2027Canadian and Mort & Co / MLA trial data release; targeted North American distribution agreement
Late Jan 2027Q2 FY2027 4C: first Ravensworth deliveries
Feb 20271H FY2027 results: evidence of revenue inflection
2027 seasonFAR / COGGO winter-crop results; Nutrien TPR sell-through; Coolum lease renewal (the right-of-use asset is nearly fully amortised)

Analyst verdict

Terragen enters FY2027 at a binary juncture. On one side is a credible, increasingly independent body of evidence:

  • a Charles Sturt University feeding trial showing roughly A$57 of extra value per carcass;

  • an independent +12% maize silage yield result for Great Land Plus;

  • a 10,600-head commercial trial co-funded by Meat & Livestock Australia's Donor Company and Mort & Co to the tune of up to A$2.8M; and

  • a Canadian government-led feedlot study, with US market access expected in December 2026.

Few micro-caps can point to this degree of third-party scrutiny. The balance sheet, at A$7.25M cash with negligible debt, buys time.

On the other side, the operating record is poor. Revenue has fallen from A$3.28M in FY2023 to A$1.43M in FY2026. The cost base of about A$6M is roughly four times revenue, losses have held at A$3.0–3.75M for four years, and every earlier commercial thesis has underdelivered: international Mylo after the 2019 IPO, the Mylo-to-TPR transition, and feedlot adoption. Repeated CFO turnover and heavy reliance on one anchor shareholder add governance and funding fragility. The 160,000-head CY2027 figure is an upside scenario, not guidance.

Our assessment is that the equity is effectively a real option on two near-term readouts: the Mort & Co / MLA trial data and a North American distribution agreement, both targeted for around January 2027. At an enterprise value of roughly A$11M, which is near the value of the cumulative non-dilutive validation now under way, the market is pricing a high probability of failure. Positive data and a signed distributor would likely trigger a re-rating and a better-priced raise. A null or ambiguous trial result would leave the company with a shrinking revenue base and a 2027–28 funding requirement, likely at dilutive terms.

Stance: speculative / event-driven. Position sizing should be keyed to the January 2027 data window rather than to the current fundamentals.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenureBackground and educationOther listed directorships (past 3 years)SharesOptions

Dr Michele Allan AO

Non-Executive Chair (since 6 Feb 2026)

—

BAppSc (UTS), MMgt (Technology) (Melbourne), DBA (RMIT), MCommLaw (Deakin), FAICD. Officer of the Order of Australia (Jan 2023). Chair of SmartSat CRC, Wine Australia, Trusted Autonomous Systems, Charles Sturt University and Twenty Degrees; NED of MJ Chickens; interim chair of the AgValue CRC bid.

Nil

Nil

3,500,000

Michael (Mike) Barry

Non-Executive Director (Chair 30 Jun 2023 – 6 Feb 2026)

Since Jun 2023 or earlier

BBus (QUT), MBA (UQ). About 10 years in senior roles at Boral; CEO of MSF Sugar for 13 years to 2020.

Entyr Limited

1,428,5725,000,000

Scobie Ward

Non-Executive Director (waives fees)

Since about Sep 2023

Started at Indosuez Asia Investment Services (1989); co-founded Lloyd George Management (1992) and Ward Ferry Management (2000, chair to 2021); pre-IPO investor

Nil

277,077,542 (indirect)

Nil

Andrew Guthrie

Non-Executive Director; Audit and Risk Committee Chair

Since 8 Jul 2024

BAgrSc (Hons) (La Trobe), GAICD. 32 years at Syngenta, including Regional Director Asia Pacific and head of Europe, Africa and Middle East. Board of Cotton Seed Distributors.

Bio-Gene Technology Ltd

285,715 (indirect)

3,500,000

Paul Whimp

Non-Executive Director

Since 8 May 2026

BBus (Acc), CA ANZ, GradDipFinPlan; director of Harris Black (accounting / advisory); former Brentnalls National chair

Carawine Resources Ltd

Nil

Nil

Richard Norton

Managing Director and CEO

CEO since 2023/2024 (sources conflict)

MBA (Monash), GAICD. Former MD of Meat & Livestock Australia (2014–2018); former MD of Landmark Operations; GM Retail at Elders; earlier roles at Wesfarmers Dalgety, Toll, Woolworths and Coca-Cola Amatil. Past boards include AuctionsPlus (Chair), Integrated Traceability Solutions (Chair), Agrium Asia Pacific and AWB. Also Food Agility CRC CEO/MD (2021 – 30 Jun 2026, per Food Agility).

Nil

571,429 (indirect)

10,000,000

Executive Leadership Team

NameTitleTenureBackground

Richard Norton

MD and CEO

See above

See above

Dr Jocelyn (Joss) West

Chief Operating Officer

Since 27 Mar 2023

Veterinarian (BVetBiol/BVSc, Charles Sturt), MBA (Griffith), GAICD. 12 years in mixed and production-animal practice; Clinical Lead at National Vet Care (2018). Holds 516,566 shares and 7.5M options.

Rebecca White

CFO (fractional, via Traverse Accountants)

Since 7 Oct 2026

Also CFO and Executive Director of Tinybeans Group (ASX:TNY); former CEO and Executive Director of Revasum (ASX:RVS)

Roger McPherson

Joint Company Secretary (CFO 11 Aug 2025 – 7 Jul 2026)

Since 11 Aug 2025

30+ years in finance; 20+ years in biotech, agtech and pharma; BBus (Curtin), CPA, GAICD. Paid A$1,500/day for 1–2 days per week.

Maree Crawford

Manager, Innovation & Adoption

Appointed June quarter 2026

Background in commercialising seeds, fertiliser and inputs

Dr Karen Jury

Head of R&D

——

Dr Paul Scott

Head of Soil Health Product Development

——

Adam Davies

Head of Sales and Marketing

——

Andrew Wollen

Head of New Product Applications Development

——

“—” = not publicly disclosed.

Directors' Remuneration

NameCash salary / feesSuperLeaveShare-basedBonus / otherTotal% performance-based

Dr Michele Allan AO

62,1437,457—34,058—103,6580%

Michael Barry

66,4297,971—48,655—123,0550%

Scobie Ward

—————

0 (fees waived)

0%

Andrew Guthrie

53,5716,429—34,058—94,0580%

Paul Whimp (from 8 May 2026)

7,866944———8,8100%

Richard Norton (MD and CEO)

260,71943,28614,36097,310100,000515,67519.4%

Jocelyn West (COO)

198,14623,778(8,468)71,785—285,2410%

Roger McPherson (CFO, consultant)

112,500————112,5000%

Matthew Whyte (to 27 Aug 2025)

50,6985,920———56,6180%

Total KMP

812,072

95,785

5,892

285,866

100,000

1,299,615

7.7%

Major Shareholders

HolderShares% of 823.2MSource

Scobie Ward (indirect, associated entities)

277,077,54233.7%

FY2026 Annual Report

Other directors and KMP combined

2,802,2820.3%

FY2026 Annual Report

Free float

—

about 29% (MarketScreener estimate)

Implies other large blockholders exist beyond Ward

Competitive Landscape

Competitors by Segment

SegmentCompetitorTypeRelative positioning

Ruminant probiotics / DFMs

Novonesis (formerly Novozymes and Chr. Hansen)

Global listed biosolutions major

Dominant in microbial strains and direct-fed microbials; vastly larger R&D and global distribution

Ruminant probiotics / DFMs

Lallemand Animal Nutrition

Global private

Established yeast and bacterial probiotics for dairy and beef

Ruminant probiotics / feed additives

DSM-Firmenich (Bovaer® methane inhibitor)

Global listed

Leader in methane-reduction feed additives; competes for the same "climate plus productivity" budget

Feed additives

Alltech

Global private

Broad feed-additive and yeast portfolio, strong in Australia and New Zealand

Feedlot performance additives

Elanco; Phibro Animal Health

Global listed animal health

Ionophores and antibiotic alternatives entrenched in feedlot rations

Methane-reduction start-ups

Rumin8 (Australia), CH4 Global, FutureFeed licensees

Private

Compete on the methane narrative and for MLA-linked validation funding

Plant biostimulants (Australia)

RLF AgTech (ASX: RLF)

Australian listed

Liquid fertilisers and biostimulants; also signed a Nutrien Australia distribution deal (Aug 2025), a direct channel overlap

Plant biostimulants / biologicals

Bioceres / ProFarm; Biome Makers; Lallemand Plant Care

Global

Broad biological crop inputs

Nitrogen-fixing microbes

Pivot Bio (US)

Private

Scale leader in nitrogen-fixing microbes, directly relevant to the QUT nitrogen project

Crop inputs majors

Syngenta Biologicals, Corteva Biologicals, BASF, Bayer

Global

Acquisitive biological portfolios with channel power

Plant biologicals (Nutrien in-house)

Nutrien (e.g., TERRAMAR bio-solution in Western Canada, 2026)

Global listed

Terragen's key Australian distributor is also developing its own biologicals, a channel-conflict risk

Companion-animal probiotics

Purina (Nestlé) FortiFlora, Zoetis, Virbac

Global

Entrenched veterinary probiotic brands

Competitor Detail

MetricTerragen (FY2026)

Revenue

A$1.43M

Revenue growth

−11.3%

Gross margin

59.3%

Net margin

−262%

R&D intensity

85.5% of revenue

Recent Developments

The FY2025 termination benefits of A$184k imply some restructuring in that year.

Company Snapshot

1996

Founded

Coolum Beach, Australia

Headquarters

SWOT Analysis

Strengths

  • Clean, liquid balance sheet after the raise. Cash of A$7.25M, total liabilities of A$1.09M and no bank debt at 30 June 2026 (FY2026 Annual Report). The going-concern forecast runs to 31 March 2028.
  • Independent efficacy data. GLP: +12% maize silage yield, about A$1,100/ha, ROI up to 20x (Laconik, 3 Mar 2026). TPR: about A$57 per carcass and up to 4.7% heavier cattle in the Charles Sturt University trial (Q4 FY2026 report).
  • Non-dilutive validation funding. Up to A$2.8M of external funding for the Mort & Co / MLA trial (Q4 FY2026 report), exceeding Terragen's own FY2026 R&D spend of A$1.22M.
  • Improving gross margin. 59.3% in FY2026, up from 49.0% in FY2025 (FY2026 Annual Report).
  • Distribution access. The Nutrien national agreement now covers the full portfolio, giving more than 700 locations (Q4 FY2026 report).
  • Industry-credentialled leadership. The CEO is a former MD of MLA; a director led Syngenta's EAME business; the Chair is an AO who chairs Wine Australia and Charles Sturt University (FY2026 Annual Report).
  • Committed anchor shareholder. Scobie Ward's entities hold 33.7% and invested A$2.25M in the 2026 placement (Market Index).

Weaknesses

  • Three consecutive years of revenue decline. Statutory revenue fell from A$3.28M (FY2023) to A$1.43M (FY2026) (FY2024 4E; FY2026 Annual Report).
  • Fixed costs far exceed gross profit. Administration alone was A$2.82M against gross profit of A$0.85M in FY2026.
  • Persistent cash burn. Operating outflows of A$3.38M in FY2026 and A$3.03M in FY2025; accumulated losses of A$48.99M.
  • Customer concentration. Two customers made up about 25% of FY2026 revenue (Note 5).
  • CFO instability. Five CFO arrangements between July 2024 and October 2026, ending in a fractional outsourced CFO (ASX, 7 Oct 2026).
  • Inventory risk. Raw materials doubled to A$0.74M; DIO is about 609 days on year-end stock (Note 9, derived).
  • Channel transition friction. The Mylo-to-TPR switch is slower than expected (FY2026 Annual Report).

Opportunities

  • CY2027 TPR volume. Up to 160,000 head if the Mort & Co trial succeeds and Ravensworth scales up (Q4 FY2026 report).
  • US market access. Approval expected December 2026 and a North American distribution agreement targeted for January 2027 (Q4 FY2026 report).
  • Nitrogen-efficiency microbes. Addresses a market of about US$67 billion (Q4 FY2026 report).
  • Companion animals. A canine probiotic with positive short-chain fatty acid data and microbiome results due November 2026.
  • Consumer channel. Naturalift extends the GLP technology to households (FY2026 Annual Report).
  • Winter-crop expansion. FAR / COGGO trial data could open the southern and Western Australian grain belts.

Threats

  • Trial failure risk. The Mort & Co supply agreement is conditional on trial success (Q4 FY2026 report).
  • Ravensworth conditions precedent. The order depends on a dispenser installation and the feedlot's own expansion. Ongoing purchases are at the customer's discretion.
  • Dilution. Shares on issue rose 123% in two years, from 369.1M to 823.2M (Note 18). Further raises are likely before profitability.
  • Distributor competition. Nutrien is commercialising its own biologicals (e.g., TERRAMAR in Western Canada, July 2026).
  • Climate volatility. Drought already cut FY2026 sales (FY2026 Annual Report).
  • Well-funded rivals. Methane inhibitors (e.g., DSM-Firmenich's Bovaer) compete for the same sustainability budgets.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Mar/Apr 2025TPR and TPR Ultra launched (dates per Annual Report vs interim report)New dry-format feedlot product line
28 Aug 2025FY2025 results: revenue down, loss widened about 24% to A$3.72MConfirms adoption headwinds
11 Aug 2025Roger McPherson appointed CFO and Company Secretary (consultant)Finance cost reduction
27 Aug 2025Matthew Whyte resigns as CFOCFO turnover
26 Sep 20257.5M employee options granted (expiry 26 Sep 2030)Retention
26 Sep 2025FY2025 Annual Report lodgedStatutory
29 Sep 2025AGM date notice (20 Nov 2025)Governance
Oct 2025Q1 FY2026 quarterly; cash at 30 Sep 2025 reported in the Nov 2025 deckLiquidity tracking
Nov 2025Naturalift® consumer launchNew channel
18 Nov 2025Investor update presentation ("diversified portfolio of animal probiotics and biostimulants")Investor relations
20 Nov 20252025 AGMGovernance
Jan 2026Q2 FY2026 quarterly; TPR sales up 87% quarter on quarter (per TradingView summary)Early TPR traction
4 Feb 2026Mort & Co Fertilisers purchase order for GLPCommercial win
6 Feb 2026A$7.0M placement at A$0.022; Michele Allan AO appointed ChairFunding and governance
16 Feb 2026Tranche 1: 126.25M shares issued (A$2.78M)Funding
19 Feb 20261H FY2026 results: revenue A$672k (−26%), loss A$1.78M (vs A$2.30M); operating outflow +48%Weak sales, lower loss
3 Mar 2026Laconik GLP maize silage: +12% yield, about A$1,100/haEfficacy validation; shares rose about 21% on the day
30 Mar 2026Tranche 2: 191.93M shares issued (A$4.22M) after shareholder approvalFunding complete
30 Apr 2026Q3 FY2026 4C: cash A$8.4MLiquidity
8 May 2026Paul Whimp joins Board; Audit and Risk Committee reconstitutedGovernance
18 May 2026Announcement of external industry funding up to A$2.8M for the TPR trial (referenced in Q4 report)Non-dilutive validation funding
28 May 2026Ravensworth supply agreement; Mort & Co trial and conditional supply agreementFirst large-scale contract; shares rose about 25–50% intraday
May–Jun 2026Dispenser installed at Grassdale; cattle inductions beginTrial execution
30 Jun 2026CEO's Food Agility contract endsFull-time focus on Terragen
7 Jul 2026Daniel Pearce appointed CFOCFO turnover
30 Jul 2026Q4 FY2026 4C: cash A$7.25M; Nutrien extension to TPR; FAR / COGGO trials; Maree Crawford hired; US approval expected Dec 2026Commercial and regulatory roadmap
Jul 2026AAFC Phase 2 cattle processedNorth American data
25 Aug 2026FY2026 results and Annual Report: revenue A$1.43M (−11.3%), loss A$3.75MStatutory
27 Aug 2026Joint Company Secretary changes (MarketScreener)Administration
2 Oct 20262026 AGM set for 27 Nov 2026; nominations closed 9 OctGovernance
7 Oct 2026Daniel Pearce resigns; Rebecca White appointed fractional CFOFifth CFO arrangement in about 27 months

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Revenue, statutory fell from AUD 2.9 Mn in FY2022 to AUD 1.4 Mn in FY2026.
Terragen Holdings Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue, statutory2.93.32.11.61.4
Net sales net of commissions, company-reported2.22.5———
Cost of sales——0.80.80.6
Gross profit——1.40.80.9
Sales and marketing expense———1.71.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Terragen Holdings, Appendix 4E and FY2026 Annual Report (25 Aug 2026) · also
  2. Terragen Holdings, Quarterly Activities Report and Appendix 4C, quarter ended 30 June 2026 (30 Jul 2026) (investorpa.com)
  3. Terragen Holdings, Appendix 4D and Interim Financial Report, half-year to 31 Dec 2025 (19 Feb 2026) (announcements.asx.com.au)
  4. Terragen Holdings, FY2024 Appendix 4E (22 Aug 2024) (announcements.asx.com.au)
  5. Terragen Holdings, FY2023 Full Year Results release (30 Aug 2023) (announcements.asx.com.au)
  6. Terragen Holdings, Quarterly Activities Report, quarter ended 31 Dec 2024 (30 Jan 2025) (investors.terragen.com.au)
  7. Terragen Holdings, AGM notice (29 Sep 2025) (bulletin.webull.com)
  8. Terragen Holdings, Investor update (Nov 2025) (bulletin.webull.com)
  9. InvestSMART announcement summaries (3 Mar 2026, 30 Apr 2026, 28 May 2026, 30 Jul 2026): ; /2519206 ; /2530480 ; /2554768 (investsmart.com.au)
  10. TradingView, A$7M placement and Chair appointment (tradingview.com)
  11. Kalkine, CFO change (7 Oct 2026) (kalkine.com.au)
  12. Kalkine Media / TipRanks, 2026 AGM notice (2 Oct 2026) · tipranks.com
  13. Stockhead, IPO Watch (2019) (stockhead.com.au)
  14. Business News Australia, ASX listing coverage (Dec 2019) (direct.businessnewsaustralia.com)
  15. StockAnalysis, income statement and balance sheet (aggregator) · stockanalysis.com
  16. Yahoo Finance, quote and profile · au.finance.yahoo.com
  17. MarketScreener, quote, management and insider data · de.marketscreener.com · marketscreener.com
  18. Market Index, director transactions (Scobie Ward, Mike Barry) · marketindex.com.au
  19. Simply Wall St, FY2025 earnings summary (simplywall.st)
  20. TipRanks, FY2025 results summary (tipranks.com)
  21. Food Agility CRC, "Thank you, Richard" (30 Jun 2026) (foodagility.com)
  22. Farms.com, Nutrien TERRAMAR launch in Western Canada (Jul 2026) (farms.com)
  23. New AG International, RLF AgTech–Nutrien distribution agreement (Aug 2025) (newaginternational.com)
  24. StockLight, TGH announcement log (stocklight.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.